In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species [PDF]
David R. Andes+5 more
openalex +1 more source
Tolerance and heteroresistance to echinocandins in <i>Candida auris</i>: conceptual issues, clinical implications, and outstanding questions. [PDF]
Shor E, Perlin DS, Kontoyiannis DP.
europepmc +1 more source
<i>Candida glabrata</i> Prosthetic Joint Infection Managed with Ibrexafungerp. [PDF]
Nadarevic E, McHugh J, Vergidis P.
europepmc +1 more source
Echinocandins - first line in invasive candidiasis: how strong is this 'strong' evidence? [PDF]
João Gonçalves-Pereira, Pedro Póvoa
openalex +1 more source
Activity of Rezafungin Against Echinocandin Non-wild type <i>Candida glabrata</i> Clinical Isolates From a Global Surveillance Program. [PDF]
Castanheira M+3 more
europepmc +1 more source
Candida auris is emerging as a prevalent urinary pathogen. [PDF]
La Bella AA+2 more
europepmc +1 more source
Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance [PDF]
Ronen Ben‐Ami+6 more
openalex +1 more source
Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates. [PDF]
Zajac C+4 more
europepmc +1 more source